Research Article
Preliminary Anticonvulsant and Toxicity Screening of Substituted Benzylidenehydrazinyl-N-(6-substituted benzo[d]thiazol-2-yl)propanamides
Table 5
Phase IV quantitative anticonvulsant evaluation of selected active compounds after oral administration.
| |||||||||||||||||||||||||||||||||||
Time of peak pharmacodynamic activity. bED50 median effective dose eliciting anticonvulsant protection in 50% animals. cTD50 median toxic dose eliciting minimal neurological toxicity in 50% animals. dPI (protective index) was determined by TD50/ED50. e95% confidence interval in parenthesis. |